Amplia Therapeutics Ltd - FDA Awards Amplia Orphan Drug Designation for Pancreatic Cancer
Amplia Therapeutics Ltd (ASX:ATX)

FDA Awards Amplia Orphan Drug Designation for Pancreatic Cancer

Highlights

What's happened?

Amplia Therapeutics Limited (ASX: ATX, “Amplia”) today announced that the United States Food and Drug Administration (FDA) has awarded Amplia’s Focal Adhesion Kinase inhibitor (FAKi) AMP945 Orphan-Drug Designation for the treatment of pancreatic cancer.

What are the key highlights?

  1. The designation means that Amplia will qualify for waived FDA fees, clinical trial protocol assistance and other incentives.
  2. If the FDA ultimately approves AMP945 for the treatment of pancreatic cancer, Amplia would qualify for seven years’ market exclusivity in FDA-administered markets.
  3. Amplia is aiming to start a Phase 1 clinical trial of AMP945 in healthy volunteers later this year to confirm that, like other FAKi, it is well tolerated.

Download Announcement

View this announcement as well as our full profile on the company.

How do I invest?

Considering investing in Amplia Therapeutics Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:ATX

    On your online investment platform search for the stock ticker code ASX:ATX to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up